anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Levocarnitine
Trial phase: Phase 2
ATC code: A16AA01
SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Patients were treated with a glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the long dwell. Peritoneal dialysis solution was instilled for 5 days.
Eligibility criteria:
Inclusion Criteria:

Age ≥18 years
Have a diagnosis of End Stage Renal Disease and have been on Continuous Ambulatory Peritoneal Dialysis for at least 3 months
Be in a stable clinical condition during the four weeks immediately prior to Screening Period as demonstrated by medical history, physical examination and laboratory testing
Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with Investigators)
Have not experienced peritonitis episodes in the last 3 months
Be treated with 3 diurnal exchange bag solutions (1.5% or 2.5% glucose) and one nocturnal exchange bag solution (2.5% glucose)
Have Kt/V urea measurement > 1.7 per week in a previous test performed within 6 months that should be confirmed at Baseline Visit
Have a minimum weekly creatinine clearance of 45 litres in a previous test performed within 6 months that should be confirmed at Baseline Visit
Have a D/P Creatinine ratio at Peritoneal Equilibration Test between 0.50 and 0.81 in a previous test performed within 6 months that should be confirmed at Baseline Visit
Have a D/P Glucose ratio at Peritoneal Equilibration Test between 0.26 and 0.49 in a previous test performed within 6 months that should be confirmed at Baseline Visit
Be treated by the participating clinical Investigator for a period of at least three months
Have understood and signed the Informed Consent Form.

Exclusion Criteria:

Have a history of drug or alcohol abuse in the six months prior to entering the protocol
Be in treatment with androgens
Have Diabetes Mellitus (as defined by the American Diabetes Society, objectively documented by a fasting plasma glucose and HbA1c determinations)
Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT > 2 times the upper normal limit)
Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc)
Have a history of congestive heart failure and clinically significant arrhythmia
Have an history of epilepsy or any central nervous system disease
Have malignancy within the past 5 years, including lymphoproliferative disorders
Have any medical condition that, in the judgment of the Investigator, would jeopardize the patient's safety following exposure to study drug, particularly if patient's life expectancy is less than 1 year
Have a history of L-Carnitine therapy or use in the month prior to entering the protocol
Have used any investigational drug in the 3 months prior to entering the protocol
Pregnant, lactating, fertility age without protection against pregnancy by adequate contraceptive means
Intervention: Eltrombopag
Trial phase: Phase 2
ATC code: B02BX05
SMILES: CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
Eligibility criteria:
INCLUSION CRITERIA:

Diagnosis of aplastic anemia, with refractory thrombocytopenia following at least one treatment course of horse or rabbit ATG/cyclosporine.
Platelet count less than or equal to 30,000/microL
Age greater than or equal to 12 years old

EXCLUSION CRITERIA:

Diagnosis of Fanconi anemia
Infection not adequately responding to appropriate therapy
Patients with a PNH clone size in neutrophils of greater than or equal to 50%
HIV positivity
Creatinine > 2.5
Bilirubin > 2.0
SGOT or SGPT > 5 times the upper limit of normal
Hypersensitivity to eltrombopag or its components
Female subjects who are nursing or pregnant or are unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential
History of malignancy other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (for instance squamous cell or other skin cancers, stage 1 breast cancer, cervical carcinoma in situ, etc)
Unable to understand the investigational nature of the study or give informed consent
History of congestive heart failure arrhythmia requiring chronic treatment, arterial or venous thrombosis (not excluding line thrombosis) within the last 1 year, or myocardial infarction within 3 months before enrollment
ECOG Performance Status of 3 or greater
Treatment with horse or rabbit ATG or Campath within 6 months of study entry. Concurrent stable treatment with cyclosporine or G-CSF is permitted.
Intervention: Sodium Nitrite
Trial phase: Phase 2
ATC code: V03AB08
SMILES: O=N[O-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Dose escalation of sodium nitrite.

Sodium Nitrite: Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
Eligibility criteria:
Inclusion Criteria:

Acute ST segment elevation myocardial infarction
Eligible for percutaneous coronary intervention

Exclusion Criteria:

Cardiogenic shock
Cardiac arrest
Prior infarct in the infarct related artery
Hemoglobinopathy, Glucose-6 Phosphate Dehydrogenase (G6PD) deficiency
Intervention: Bivalirudin
Trial phase: Phase 1 | Phase 2
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
Eligibility criteria:
INCLUSION CRITERIA:
Participant must be scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the National Institutes of Health (NIH) Clinical Center.
Recent (within 12 months of study entry) trans-rectal biopsy indicating the presence of adenocarcinoma of the prostate gland in which at least sextant biopsies were obtained. Knowledge of the location of each specimen is required for inclusion.
Participant must be 18 years or older.
Serum creatinine within 1 week prior to magnetic resonance (MR) imaging less than or equal to 1.8mg/dl AND epidermal growth factor receptor (eGFR) must be greater than 30 ml/min/1.73 m^2
Eastern Cooperative Oncology Group (ECOG) Performance score of 0 or 1.
Ability to provide informed consent. All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed.

EXCLUSION CRITERIA:

Known allergy to gadolinium or acetate.
Participants for whom participating would significantly delay the scheduled standard of care therapy.
Participants with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results are excluded.
Participants with severe claustrophobia.
Patients with contraindications to magnetic resonance imaging (MRI)
Patients weighing greater than 136 kg (weight limit for scanner table).
Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or other implanted electronic devices or metal not compatible with MRI.
Patients with contraindication to endorectal coil placement
Severe hemorrhoids.
Surgically absent rectum.
Other medical conditions deemed by the principal investigator (PI) or associates to make the patient ineligible for protocol procedures.
Patients who have previously received radiation therapy to the pelvis.
Patients who have received androgen deprivation therapy.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: saline for sinus rinse

Saline: saline for sinus rinse
Eligibility criteria:
We now have two arms to this study.

Group I: Immunocompetent subjects with chronic rhinosinusitis

Inclusion Criteria:

56 Adult subjects (18 or older) presenting to the ENT(ears, nose, throat) clinics who meet the diagnosis of chronic rhinosinusitis (CRS). Definition of CRS: Presence of at least 2 of the following 4 signs/symptoms for 12 weeks or longer despite medical management:

Anterior and/or posterior mucopurulent drainage
Nasal obstruction
Facial pain, pressure, and/or fullness
Decreased sense of smell
In addition, objective evidence of sinus mucosal disease must be demonstrated on sinus CT imaging or direct endoscopic examination.

Exclusion Criteria:

Cystic fibrosis
Fungal sinusitis
Immunocompromised status (use of long term oral steroids (> 30 days), AIDS, active malignancy or chemotherapy)
Known Ciliary disorders
Sinonasal tumors
Pregnancy

Group 2: CRS with antibody deficiency

56 Adult subjects (18 or older) presenting to the Allergy clinic who meet the diagnosis of chronic rhinosinusitis (CRS). Definition of CRS: Presence of at least 2 of the following 4 signs/symptoms for 12 weeks or longer despite medical management:

Anterior and/or posterior mucopurulent drainage
Nasal obstruction
Facial pain, pressure, and/or fullness
Decreased sense of smell
In addition, objective evidence of sinus mucosal disease must be demonstrated on sinus CT imaging or direct endoscopic examination.

Exclusion criteria:

Cystic Fibrosis Sinonasal tumors Pregnancy
Intervention: ETHINYL ESTRADIOL
Trial phase: Phase 2
ATC code: G03AA07 | G03CA01 | L02AA03
SMILES: C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
Sex: Female
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 421
Group description: Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
Eligibility criteria:
Inclusion Criteria:

Healthy postmenarchal adolescent female 12-18 years old, non-pregnant, nonlactating
Regular spontaneous menstrual cycles
Body mass index (BMI): 18 kg/m² to <30 kg/m², weight < 200 lbs
Others as dictated by the Food and Drug Administration (FDA)-approved protocol

Exclusion Criteria:

Any contraindication to the use of oral contraceptives
History of previous clinically significant adverse event while taking hormonal contraceptives
Use of any medication which could significantly interfere with study assessments
Others as dictated by FDA-approved protocol
Intervention: Moxifloxacin Hydrochloride
Trial phase: Phase 4
SMILES: COc1c(N2CC3CCCNC3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: The patients in this group received one drop of moxifloxacin every 10 minutes for a total of 4 doses, with the last dose given 30+-2 minutes prior to the time of initiating the cataract incision.
Eligibility criteria:
Inclusion Criteria:

Subjects who have a visually significant cataract and are planning to have cataract surgery.
Subjects who are willing/able and have signed informed consent approved by the Institutional Review Board.

Exclusion Criteria:

Subjects who have a known hypersensitivity, allergy, or contraindication to any fluoroquinolone medication, in any form.
Subjects who signs of ocular infection or active inflammation in the study eye.
Subjects who have corneal pathology, including epithelial defect, corneal scarring, or severe dry eye syndrome.
Subjects who have used any disallowed medication (including antibiotics) during the time period designated as described in the protocol.
Subjects who have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and is likely to increase the risk of infection to the patient or confound the results of the study.
Subjects who are pregnant (or suspect to be pregnant) or nursing/lactating.
Subjects who have participated in any study of an investigational drug or device within 30 days prior to enrollment.
Intervention: Besifloxacin Hydrochloride
Trial phase: Phase 4
SMILES: Cl.NC1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: The patients in this group received one drop of besifloxacin every 10 minutes for a total of 4 doses, with the last dose given 30+-2 minutes prior to the time of initiating the cataract incision.
Eligibility criteria:
Inclusion Criteria:

Subjects who have a visually significant cataract and are planning to have cataract surgery.
Subjects who are willing/able and have signed informed consent approved by the Institutional Review Board.

Exclusion Criteria:

Subjects who have a known hypersensitivity, allergy, or contraindication to any fluoroquinolone medication, in any form.
Subjects who signs of ocular infection or active inflammation in the study eye.
Subjects who have corneal pathology, including epithelial defect, corneal scarring, or severe dry eye syndrome.
Subjects who have used any disallowed medication (including antibiotics) during the time period designated as described in the protocol.
Subjects who have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and is likely to increase the risk of infection to the patient or confound the results of the study.
Subjects who are pregnant (or suspect to be pregnant) or nursing/lactating.
Subjects who have participated in any study of an investigational drug or device within 30 days prior to enrollment.
Intervention: Sorafenib
Trial phase: Phase 1 | Phase 2
ATC code: L01EX02 | L01XE05
SMILES: CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.

Leuprolide acetate, Bicalutamide, Sorafenib: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
Eligibility criteria:
Inclusion Criteria:

Patients must have histologically confirmed intermediate or high risk prostate adenocarcinoma. Intermediate risk disease comprises T2b/c tumors, Gleason 7 histology, or PSA 10-20. High risk tumors comprise T3-4, Gleason 8 or higher histology, or PSA greater than 20.
Age > 18 years.
Life expectancy of greater than 5 years.
Patients must have normal organ and marrow function.
No pelvic lymph node metastases based on pelvic CT scan or MRI.
No bone metastasis. A whole body bone scan is required to rule out metastatic disease.

Exclusion Criteria:

Any previous, radiotherapy, or chemotherapy, or more than 4 weeks of androgen deprivation hormonal therapy for the treatment of prostate adenocarcinoma.
Patients may not be receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib or other agents used in this study.
Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin will not be allowed to participate.
Intervention: Atenolol
Trial phase: Phase 4
ATC code: C07AB03 | C07BB03 | C07CB03 | C07CB53 | C07DB01 | C07FB03
SMILES: CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Participants will receive atenolol for 8 weeks.

Atenolol: 12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes
Pre-Diabetes

Exclusion Criteria:

Insulin therapy
Treatment with any beta-blocker in the 30 days before study entry
Asthma
Chronic obstructive pulmonary disease (COPD)
Greater than first degree heart block
Heart rate less than 60 bpm
Systolic blood pressure less than 90 mm Hg
Raynaud's phenomenon
Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators
Pregnant
Creatinine clearance less than 35 ml/min
Hematologic dysfunction (white blood cell [WBC] count less than 3000 or hematocrit less than 28%)
Allergy to amide anesthetics
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 1 ounce of lidocaine gel applied the skin of the breasts and chest wall covered by plastic wrap for one hour
Eligibility criteria:
Inclusion Criteria:

35 years and older
intact skin on breasts and chest wall

Exclusion Criteria:

sensitivity or allergy to lidocaine
liver or kidney dysfunction
pregnant
breast feeding
currently smoke or chew tobacco
used lidocaine products within 48 hours of baseline lab, EKG, or gel application
exhibit neurological or cardiac signs or symptoms prior to gel application
are taking antiarrythmic medications, ciprofloxacin, erythromycin products, or oral contraceptives
history of Wolffe-Parkinson-White Syndrome (WPW) or congestive heart failure
heart rate below 60 or above 100 beats per minute
systolic blood pressure below 95 or above 180 mm Hg
PR interval greater 200 msec, QRS duration greater than 120 msec, QTc greater than 450 msec, or evidence of WPW on EKG
have an automatic implantable cardioverter defibrillator (AICD) or cardiac pacemaker
have had cancer, surgery, trauma, or myocardial infarction in the past 6 months
Intervention: Maraviroc
Trial phase: Phase 4
ATC code: J05AX09
SMILES: Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Maraviroc will be added to patient's existing HIV treatment regimen dose-adjusted to background HIV medications

Maraviroc: Maraviroc will be given dose-adjusted to background HIV treatment
Eligibility criteria:
Inclusion Criteria:

HIV-1 infection
All available CD4+ T cell counts within the last 12 months of screening below 350 cells/mm3 (minimum of 3 values obtained > 30 days apart).
HIV treatment with a stable (for at least 6 months) antiretroviral regimen consisting of at least 2 NRTIs and either a protease inhibitor boosted with low dose ritonavir or an NNRTI. A stable regimen is defined as no additions or deletions for more than 14 cumulative days.
Patient considered to be receiving initial HIV regimen (history of medication substitution for toxicity is allowed).
All available plasma HIV RNA levels within the last 12 months are below the level of detection. Isolated values that are detectable but < 1000 copies will be allowed as long as the plasma HIV RNA levels before and after this detectable time point are undetectable - The subject should have a minimum of 3 values obtained > 30 days apart.
Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.
Men and women age ≥ 18 years.

Exclusion Criteria:

Current antiretroviral regimen contains tenofovir disoproxil fumarate AND didanosine in combination.
History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA detectable).
History of chronic active hepatitis B (defined as surface antibody negative, surface antigen positive and HBV DNA detectable).
Concurrent use of G-CSF or GM-CSF.
Prior or concurrent use of IL-2.
Prior or concurrent use of a CCR5 inhibitor.
Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry.
Use of human growth hormone within 30 days prior to study entry.
Initiation of testosterone or anabolic steroids within 30 days prior to study entry. (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is allowed).

Evidence of splenic sequestration or suppressed bone marrow function:

Clinical or radiographic evidence of significant splenomegaly.
History of leukemia or lymphoma.
History of myelosuppressive chemotherapy or irradiation
Intervention: TERIPARATIDE
Trial phase: Phase 2
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: teriparatide: teriparatide: 20 mcg SC QD
Eligibility criteria:
Inclusion Criteria:

Must satisfy A and B and C and D below:

(A) Women aged > 55
(B) Postmenopausal
(C) Osteoporotic with high risk of fracture

Exclusion Criteria:

Confirmed serum alkaline phosphatase above upper normal limit with no explanation
Liver disease (AST or ALT > 2 x upper normal limit).
Renal disease (serum creatinine > 2.0 mg/dl).
Hypercalcemia (Ca >10.5 mg/dL)
Elevated blood PTH (intact PTH > 65 pg/ml)
Serum 25-OH vitamin D < 20 ng/ml
HCT < 32%.
History of malignancy (except basal cell carcinoma) or radiation therapy.
Significant cardiopulmonary disease including unstable coronary artery disease, stage D ACC/AHA heart failure or any other condition that the investigator deems may preclude the subject from participating safely or completing the protocol procedures.
Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
Known congenital or acquired bone disease other than osteoporosis (including osteomalacia, hyperparathyroidism, Paget's disease)
Current use or use in the past 6 months of oral bisphosphonate
Current use or use within the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin.
Use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months.
Any current or previous use of strontium or any parenteral bisphosphonate.
Known sensitivity to mammalian cell-derived drug products.
Known sensitivity to teriparatide or any of its excipients.